CapsoVision, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CV research report →
Range $9 – $9
Price Chart
About the company
CapsoVision, Inc. , a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
- CEO
- Kang-Huai Wang
- IPO
- 2025
- Employees
- 99
- HQ
- Saratoga, CA, US
Get TickerSpark's AI analysis on CV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $327.56M
- P/E
- -10.02
- Fwd P/E
- 25.46
- PEG
- 0.46
- P/S
- 23.53
- P/B
- 11.72
- EV/EBITDA
- -10.62
- Div Yield
- 0.00%
- Gross Margin
- 49.69%
- Op Margin
- -212.05%
- Net Margin
- -210.09%
- ROE
- -160.22%
- ROIC
- -108.73%
Latest fiscal year · YoY change
- Revenue
- $13.55M+15.3%
- Gross Profit
- $7.17M+12.5%
- Op Income
- $-25,516,000
- Net Income
- $-25,315,000-27.2%
- EPS
- $-0.54-25.6%
- OCF Growth
- -13.8%
- FCF Growth
- -13.4%
- 52W High
- $15.37
- 52W Low
- $4.50
- 50D MA
- $6.54
- 200D MA
- $6.41
- Beta
- -2.36
- RSI (14)
- 42
- Avg Volume
- 173.59K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CapsoVision said Q3 was marked by FDA clearance and U.S. launch of AI Highlights, completion of colon-study enrollment, and a strengthened cash position, while revenue stayed roughly flat and margins were pressured.· November 12, 2026
- FDA cleared AI Highlights for CapsoCam Plus on September 25, and the product officially launched in the U.S. on November 2.
- CapsoCam Colon completed clinical study enrollment and data collection, and management said it remains on track to submit to the FDA before year-end 2026.
- Third-quarter revenue was $3.6 million, up 1% from $3.5 million a year ago; gross margin was 49% versus 54% last year.
- The company ended September 30 with $21.8 million in cash and cash equivalents after an $18 million registered direct offering, plus $1.7 million from ATM sales in Q3.
- Management said the second half of 2026 revenue should be higher than the first half, with the full impact of AI Highlights expected in 2027.
Third-quarter revenue was $3.6 million, compared with $3.5 million in Q3 2025, up 1%. Gross profit was $1.8 million versus $1.9 million last year, and gross margin was 49% compared with 54% in the prior-year quarter, pressured by higher flash-memory costs, inventory obsolescence, and stock-based compensation. Net loss was $7.3 million, or $0.15 per share, compared with a net loss of $7.9 million, or $0.17 per share, a year ago. Operating expenses were $9.1 million versus $9.9 million last year. The company ended September 30 with $21.8 million in cash and cash equivalents, including net proceeds of about $17.8 million from a registered direct offering; it also raised $1.7 million net from 276,446 ATM shares in Q3. Management reiterated that revenue in the second half of 2026 should be higher than the first half, and said AI Highlights should drive accelerating CapsoCam Plus sales, with the full impact realized in 2027.
Johnny Wang framed the quarter as a set of strategic milestones: FDA clearance and launch of AI Highlights, completion of the colon-study data collection, and financing that supports the next stage of execution. He emphasized the differentiated 4-camera, 360-degree small-bowel imaging platform combined with AI and cloud workflow, saying it should improve review speed, accuracy, and physician confidence. His tone was constructive and forward-looking, with repeated focus on expanding the platform from small bowel into a much larger colon opportunity and longer-term pipeline programs.
David Garcia said commercial performance was shaped by a competitive pricing environment in U.S. small-bowel capsule endoscopy, but the company still added 34 new accounts, including 9 hospital systems, 4 pediatric hospital clinics, and 21 adult GI clinics. He cited Q3 revenue of $3.6 million, gross margin of 49%, operating expenses of $9.1 million, and net loss of $7.3 million, while noting margin pressure from flash-memory inflation, a one-time inventory obsolescence charge, and higher stock-based compensation. On liquidity, he said cash and cash equivalents were $21.8 million at September 30, aided by about $17.8 million in net proceeds from the registered direct offering and $1.7 million net from ATM issuance, and he said the capital extends the expected runway. He also said clinical expenses tied to the colon study should fall now that the study is complete, creating room for further OpEx decline.
Analysts focused on early feedback from AI Highlights, the remaining steps for the colon submission, the revenue mix between hospital systems and GI clinics, and how adoption may unfold in 2027. Management said early U.S. and international feedback on AI Highlights has been very positive, citing one example where AI identified 2 AVMs that were missed in a non-AI read. On the colon program, management said all data have been collected and frozen, the statistician is working on endpoints, and they are preparing the submission after that analysis. Doug Atkinson also said the current revenue mix is about 65% GI clinics and 35% hospital systems, and that hospital-system contracts can ramp fairly quickly once onboarding is complete, though some customers may first use up competitive inventory.
The call showed several concrete catalysts: FDA clearance and U.S. launch of AI Highlights, completion of the colon study, and a larger cash balance to fund execution. Management believes AI Highlights improves reading speed, diagnostic accuracy, and physician confidence, and they said customer response has been encouraging so far. The colon platform could open a much larger market over time, and management expects the second half of 2026 to be stronger than the first half.
The quarter showed only modest revenue growth, and gross margin fell to 49% from 54% because of higher material costs, inventory obsolescence, and stock-based compensation. Management also described the U.S. small-bowel market as competitive on pricing, which can limit near-term monetization even as the company expands its customer base. The colon business and AI rollout are still early, and management said the full sales impact of AI Highlights will not be realized until 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 7.9%
- Shares Outstanding
- 53.61M
- Float Shares
- 4.21M
of shares held by institutions
52 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.33M | ▲ 431.79K |
| Vanguard Capital Management LLC | 1.34M | ▲ 283.37K |
| Geode Capital Management, LLC | 852.67K | ▲ 274.19K |
| State Street Corp | 487.07K | ▲ 76.83K |
| Vanguard Fiduciary Trust Co | 260.90K | ▲ 157.27K |
| Vanguard Portfolio Management LLC | 244.55K | ▲ 4.12K |
| Vanguard Group Inc | 134.18K | ▲ 64.60K |
| Ubs Group AG | 132.65K | ▲ 125.35K |
| Charles Schwab Investment Management Inc | 85.04K | ▲ 5.68K |
| Bank Of New York Mellon Corp | 75.39K | ▲ 366 |
| Goldman Sachs Group Inc | 65.02K | ▲ 46.40K |
| Nuveen, LLC | 46.08K | ▲ 69 |
Held by 84 ETFs
Biggest fund positions in CV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | HARARI ELIYAHOU ET AL | buy | 878,735 |
| Sep 18, 26 | HARARI ELIYAHOU ET AL | buy | 878,734 |
| Apr 17, 26 | Shen Ching Hang | other | 3,991,606 |
| Apr 17, 26 | Shen Ching Hang | other | 3,991,606 |
| Sep 15, 26 | Shen Ching Hang | buy | 878,734 |
| Sep 15, 26 | Shen Ching Hang | buy | 878,734 |
| Jul 17, 26 | HARARI ELIYAHOU ET AL | buy | 61,068 |
| Jul 8, 26 | HARARI ELIYAHOU ET AL | buy | 81,300 |
| Jun 26, 26 | HARARI ELIYAHOU ET AL | buy | 13,850 |
| Jul 1, 26 | Shields David Stanley | other | 1,710 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CV coverage
Recent articles, reports, and earnings notes.
No research on CV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CV report →CapsoVision, Inc. (CV) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
What CapsoVision (CV) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
CapsoVision Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 12
CapsoVision (NASDAQ:CV) Share Price Crosses Above 200 Day Moving Average – What’s Next?
defenseworld.net · Nov 10
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
globenewswire.com · Oct 29
CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening
marketbeat.com · Oct 24
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
gurufocus.com · Oct 17
CapsoVision to Present at the 20th Annual LD Micro Main Event
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.